Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis

Zhang, Qianqian; Shi, Wenhua; Wang, Qingting; Zhu, Yanting; Zhai, Cui; Wang, Jian; Yan, Xin; Chai, Limin; Li, Manxiang

doi:10.7150/jca.24749

International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

open access Global reach, higher impact

Full Text | PDF

J Cancer 2018; 9(16):2895-2909. doi:10.7150/jca.24749 This issue Cite

Research Paper

Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis

Qianqian Zhang, Wenhua Shi, Qingting Wang, Yanting Zhu, Cui Zhai, Jian Wang, Xin Yan, Limin Chai, Manxiang Li^✉

Department of Respiratory and Critical Care Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, China

Citation:

Zhang Q, Shi W, Wang Q, Zhu Y, Zhai C, Wang J, Yan X, Chai L, Li M. Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis. J Cancer 2018; 9(16):2895-2909. doi:10.7150/jca.24749. https://www.jcancer.org/v09p2895.htm

Other styles

Abstract

Background: Accumulating studies have demonstrated that the expression of leucine-rich repeats and immunoglobulin-like domains protein1 (LRIG1) is associated with various types of tumors. However, the conclusions of previous studies are not completely consistent. Thus, we conducted this meta-analysis to further explore the authentic value of LRIG1 in cancer outcome and clinical significance.

Methods: We systematically searched electronic databases including PubMed, Web of Science, Embase, Chinese National Knowledge Infrastructure and Wanfang database. The hazard ratios (HRs), odds ratio (OR) and 95 % confidence intervals (CI) were calculated for effect measures.

Results: 16 qualified studies involving 2043 patients with cancer were enrolled. High LRIG1 expression was associated with a good prognosis in malignant tumors (HR: 0.49, 95% CI=0.39-0.59). Furthermore, positive expression rate of LRIG1 was distinctly lower in cancer tissues than that in normal tissues (OR: 0.09, 95% CI=0.05-0.17). Positive LRIG1 expression was definitely related with smaller tumor size (OR: 1.64, 95% CI=1.11-2.42), early tumor stage (OR: 3.67, 95% CI=1.87-7.21), well degree of differentiation (OR: 4.35, 95% CI=2.12-8.93) and negative recurrence (OR: 0.29, 95% CI=0.16-0.53).

Conclusions: LRIG1 expression was associated with a good prognosis in terms of overall survival (OS) and might act as a predictive factor for characteristics of cancer patients.

Keywords: leucine-rich repeats and immunoglobulin-like domains protein1, tumor, meta-analysis

Citation styles

APA

Zhang, Q., Shi, W., Wang, Q., Zhu, Y., Zhai, C., Wang, J., Yan, X., Chai, L., Li, M. (2018). Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis. Journal of Cancer, 9(16), 2895-2909. https://doi.org/10.7150/jca.24749.

ACS

Zhang, Q.; Shi, W.; Wang, Q.; Zhu, Y.; Zhai, C.; Wang, J.; Yan, X.; Chai, L.; Li, M. Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis. J. Cancer 2018, 9 (16), 2895-2909. DOI: 10.7150/jca.24749.

NLM

CSE

Zhang Q, Shi W, Wang Q, Zhu Y, Zhai C, Wang J, Yan X, Chai L, Li M. 2018. Clinicopathological and prognostic significance of leucine-rich repeats and immunoglobulin-like domains protein 1 (LRIG1) in malignant tumors: A meta-analysis. J Cancer. 9(16):2895-2909.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.